Abstract: The present invention provides a method of inducing sleep in a host which includes administering to the host synthetic peptides, as well as fragments and analogs thereof, complementary to growth hormone releasing hormone.

Abstract: Calcitonin derivatives wherein at least one of the first cysteine residue and the seventh cysteine residue is S-sulfonated; processes for the production of the calcitonin derivatives comprising the steps of reacting a calcitonin with a sulfite anion or both a sulfite anion and an oxidizing agent to form the S-sulfonated derivative, and recovering the sulfonated calcitonin derivative; a pharmaceutical composition comprising the S-sulfonated calcitonin derivative; and a method of treating a patient having a disease wherein a decrease of a serum calcium level is desired, by administering the S-sulfonated calcitonin derivative to the patient.

Abstract: A polypeptide having the following formula is provided: gly-glu-phe-tyr-phe-asp-leu-arg-leu-lys-gly-asp-lys which can bind heparin and promote cellular adhesion.Medical devices such as prosthetic implants, percutaneous devices and cell culture substrates coated with a composition including the polypeptide are also provided.

Abstract: Novel peptide derivatives of the following formula ##STR1## wherein each symbol is as defined in the specification, pharmaceutically acceptable acid addition salts thereof and analogous copounds thereof.Since the derivatives and their pharmaceutically acceptable acid addition salts of the present invention possess stronger actions on central nervous system (e.g. antagonistic action against hypothermia, locomotor stimulant action, signal reflex stimulant action), they are of use as a therapeutic medicament for central nervous disorders such as impaired consciousness, depression, hypomnesia, the like in association association with schizophrenia, melancholia, senile dementia, sequelae of cerebrovascular disorders, head trauma, epilepsy and spinocerebellar degeneracy.

Abstract: A method for inhibiting blood vessel blockage in a mammal particularly after a procedure such as angioplasty, an arterial bypass operation or an allograft transplant operation which comprises: administering to a mammal before, during and/or after the procedure an effective blood vessel blockage inhibiting amount of an octapeptide having the formula ##STR1## wherein each A.sub.1 and A.sub.2, independently, is H, C.sub.1-12 alkyl, C.sub.7-10 phenylalkyl, R.sub.1 CO (where R.sub.1 is C.sub.1-20 alkyl, C.sub.3-20 alkenyl, C.sub.3-20 alkinyl, phenyl, naphthyl, or C.sub.7-10 phenylalkyl), or R.sub.2 OCO (where R.sub.2 is C.sub.1-10 alkyl or C.sub.7-10 phenylalkyl), provided that when one of A.sub.1 or A.sub.2 is R.sub.1 CO or R.sub.2 OCO, the other must be H; A.sub.3 is CH.sub.2 A.sub.6 (where A.sub.6 is pentafluorophenyl, naphthyl, pyridyl, or phenyl); A.sub.4 is o-, m- or, more preferably, p-substituted X-Phe (where X is a halogen, H, NH.sub.2, NO.sub.2, OH , or C.sub.1-13 alkyl), pentafluoro-Phe, or .beta.

Abstract: Dipeptide mimics which contain phosphorus and their pharmaceutical use and preparation are disclosed. The compounds have dehydropeptidase (DHP) enzyme inhibitor activity.

Abstract: Benzyl esters of the formula I ##STR1## where R.sup.1 is methyl, ethyl, halogen, methoxy or ethoxy, R.sup.2 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl, C.sub.1 -C.sub.5 -alkyl-substituted cycloalkyl, C.sub.1 -C.sub.5 -substituted cycloalkenyl, C.sub.1 -C.sub.5 -alkyl-substituted bicycloalkyl or C.sub.1 -C.sub.5 -alkyl-substituted bicycloalkenyl, R.sup.3 is hydrogen, cyano, C.sub.2 -C.sub.4 -alkynyl, C.sub.2 -C.sub.4 -alkenyl or C.sub.1 -C.sub.4 -alkyl, A is the carboxylate radical of an acid component typical for pyrethroids and X is hydrogen or halogen, with the proviso that R.sup.2 is not CH.sub.2 --CH.dbd.CH--B when B is hydrogen, alkyl or alkenyl and at the same time R.sup.1 is methyl or halogen, and furthermore with the proviso that R.sup.2 is not methyl when R.sup.1 is methyl, their manufacture, their use for combating pests, and precursors for manufacturing the benzyl esters.

Abstract: There are provided pharmaceutical compositions for topical transdermal application for the treatment of male impotence. The active ingredients of such compositions are selected from vasoactive intestinal peptide (VIP), effective derivatives thereof and effective fragments thereof. In the compositions for the treatment of male impotence a transdermally effective conjugate of VIP, its derivatives or fragments coupled to a hydrophogic moiety, is used.

Abstract: Compounds of the formula ##STR1## wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and n have the meanings reported in the specification, processes for their preparation and pharmaceutical compositions containing them as active ingredient are described.The compounds of formula I are inhibitor of enzymatic systems and they are useful in pharmaceutical field.

Abstract: Disclosed is a rinse for preservation solution for organs and tissues selected for transplantation. The solution can be used at all temperatures from 0.degree. C. to normal body temperature and continues to be protective above 10.degree. C. Methods for preparing organs and tissues preserved in a preservation solution prior to transplant into a recipient are also disclosed.

Abstract: A variety of compositions suitable for use with methods for (a) reducing the formation of stomach ulcers in warm-blooded animals, (b) reducing the secretion of stomach acid in warm-blooded animals, (c) increasing the secretion of cytoprotective mucous in the stomach of warm-blooded animals, and (d) healing established stomach or intestinal ulcers in warm-blooded animals are disclosed. The compositions include glycyl-L-histidyl-L-lysine, L-lysyl-L-histidyl-glycine, L-lysyl-L-histidyl-glycine:copper (II), glycyl-L-histidyl-L-lysine:copper (II), and derivatives thereof.

Abstract: Active substances intended for topical application are incorporated in novel formulations in which they are retained as impregnants inside the pores of porous solid particles or microspheres. The pores form a continuous network open to the exterior of the particles, permitting outward diffusion of the impregnants at a controlled rate depending on the pore size. The impregnated particles are prepared by impregnation of preformed particles with the active substance.

Abstract: Compounds of peptide nature presenting a sequence of three aminoacids, in particular with PYR and TRP as terminal groups, are found to be active as immunomodulating agents.

Abstract: Novel recombinant HTLV-III fusion proteins denoted R10, PB1, 590, KH1, and the HIV portion of each of these proteins are useful in the diagnosis, prophylaxis or therapy of AIDS. Protein R10 is a 95 kD fusion protein; protein PB1 is a 26 kD fusion protein; protein 590 is an 86 kD fusion protein; and protein KH1 is a 70 kD fusion protein. These proteins are considered to be especially useful to prepare vaccines for the HTLV-III virus.

Abstract: Granules prepared by absorbing on hydrophilic polymer granules an aqueous emulsion of at least one active principle and drying the resulting mixture to obtain granules which release the active principle in uniform manner.

Abstract: Pesticides containing at least one compound of the formula I ##STR1## where M denotes carbon or silicon,X denotes CH.sub.2, O, S, NR.sup.6,R.sup.1 denotes (C.sub.2 -C.sub.18)alkyl, (C.sub.5 -C.sub.7)cycloalkyl, (C.sub.2 -C.sub.8)alkenyl, phenyl, naphthyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, 1,2,4-triazinyl or 1,2,4,5-tetrazinyl, it being possible for all these substituents to be monosubstituted or polysubstituted,R.sup.2, R.sup.3 independently of one another denote (C.sub.1 -C.sub.3)alkyl, (C.sub.2 -C.sub.8)alkenyl or phenyl, or R.sup.2 and R.sup.3 denote an alkylene chain which--together with the quaternary central atom (M)--form an unsubstituted or fluorine-substituted ring having four to six ring members (where M=Si) or having three to six ring members (where M=C),R.sup.4 denotes --H, --CN, --CCl.sub.3, --C.tbd.CH, (C.sub.1 -C.sub.4)alkyl, F, ##STR2## R.sup.5 denotes pyridyl, furyl or thienyl, each of which can be substituted, phthalimidyl, di(C.sub.1 -C.sub.

Abstract: A method of determining collagen degradation in vivo, including quantitating the concentration of a peptide in a body fluid, the peptide being a C-terminal type II collagen telopeptide containing a hydroxylysyl pyridinoline cross-link or a type III collagen telopeptide containing a hydroxylysyl pyridinoline cross-link. The method includes immunometric assays, fluorometric assays, and electrochemical titrations for quantitation. The structures of specific peptides having cross-links and kits for quantitating these peptides in a body fluid are described.

Abstract: A method is provided for preventing or reducing the risk of restenosis following angioplasty by administering pravastatin alone or in combination with an ACE inhibitor such as captopril or ceranapril, prior to, during and/or after angioplasty.

Abstract: The invention provides a superoxide dismutase derivative of the general formula[SOD][Z].sub.nwherein [SOD] represents a superoxide dismutase having 1 to 22 or 24 groups each derived from an amino group by removal of one hydrogen atom in lieu of amino groups; [Z] represents a monovalent copolymer group, constituting units of which are a group of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 each represents a hydrogen atom or a residue derived by removal of a hydroxyl group from an alkanol of 1 to 8 carbon atoms, an ethylene glycol monoalkyl ether containing an alkyl moiety of 1 to 4 carbon atoms or a glycerin dialkyl ether containing alkyl moieties of 1 to 4 carbon atoms, provided that either R.sup.1 or R.sup.2 and either R.sup.3 or R.sup.4 each represents a hydrogen atom, and a residue derived from the group of the above-mentioned formula by removal of OR.sup.1, OR.sup.2, OR.sup.3 or OR.sup.4 group from one of its COOR.sup.1, COOR.sup.2, COOR.sup.3 and COOR.sup.

Abstract: Administration of a Corticotropin-Releasing Factor (or a salt of analog thereof) decreases the leakage of blood components into brain tissue produced by various adverse medical conditions and reduces bleeding when muscle tissues are cut and handled, such as in plastic and reconstructive surgery. A method of treating a patient for injury to or disease of the brain, central nervous system, or musculature in which edema is a factor comprises administering to the patient a Corticotropin-Releasing Factor (or salt or analog) in an amount effective to decrease vascular permeability in the injured or diseased brain, nervous system tissue or musculature, and thereby to reduce edema. Administration in accordance with the method can be about two hours before surgery, or can be up to three days after injury.